【摘要】 肺纤维化是一种慢性进行性疾病，其特征是肺部组织受损，逐渐被纤维组织替代，导致肺功能受损。现有疗法存在疗效有限和不良反应明显等问题。近年来，研究发现，肠道菌群调控在肺纤维化发病过程和中药治疗进展中发挥了重要作用，为基于肠道菌群靶点研究肺纤维化发病机制及中药新药研发提供理论依据和实践方向。现已有研究表明，中药活性成分、单味中药及中药复方在治疗肺纤维化过程中通过重塑肠道菌群平衡、调控菌群代谢产物生成，并强化肠道屏障功能与肠道免疫调节，从而实现抗肺纤维化效果。本文作者从肠道菌群调控肺纤维化的作用机制及中药基于肠道菌群靶点治疗肺纤维化进行综述，以期为中药治疗肺纤维化作用机制提供理论依据及抗肺纤维化中药新药研发提供策略支持。更多还原

【Abstract】 Pulmonary fibrosis is a chronic progressive disease characterized by damage to lung tissue, which is gradually replaced by fibrous tissue, leading to impaired lung function.Current treatments are limited by insufficient efficacy and significant side effects.In recent years, studies have revealed that gut microbiota regulation plays a crucial role in the pathogenesis of pulmonary fibrosis and the progress of traditional Chinese medicine(TCM) treatment, providing theoretical basis and practical directions for researching the pathogenesis of pulmonary fibrosis and developing new drugs targeting the gut microbiota.Existing studies have demonstrated that TCM active ingredients, single herbs, and TCM formulas achieve antifibrotic effects in pulmonary fibrosis treatment by reshaping the balance of gut microbiota, regulating the generation of microbial metabolome, reinforcing intestinal barrier function and intestinal immune regulation.This paper reviews the mechanisms of gut microbiota regulation in pulmonary fibrosis and TCM targeting the gut microbiota for pulmonary fibrosis treatment, providing theoretical basis for exploring the mechanism of TCM against pulmonary fibrosis and strategies for developing novel TCM drugs.更多还原